NEW YORK, Jan. 24, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on XXII, ABEO, ACST, and AEZS which can be accessed for free by signing up to www.wallstequities.com/registration. On Tuesday, the NASDAQ Composite ended the day at 7,460.29, up 0.71%; the Dow Jones Industrial
22nd Century Group
Clarence, New York headquartered 22nd Century Group Inc.'s stock finished Tuesday's session 4.81% lower at $3.96 with a total trading volume of 14.91 million shares, which was above its three months average volume of 3.44 million shares. The stock has gained 54.69% in the past month, 48.87% over the past three months, and 332.79% in the previous twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 46.36% and 82.91%, respectively. Moreover, shares of 22nd Century, which provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding, have a Relative Strength Index (RSI) of 71.39. Get the full research report on XXII for free by clicking below at: www.wallstequities.com/registration/?symbol=XXII
Shares in Dallas, Texas-based Abeona Therapeutics Inc. rose 3.70%, ending yesterday's session at $15.40 with a total trading volume of 1.09 million shares, which was above its three months average volume of 776.74 thousand. The stock has gained 214.29% over the past twelve months. The Company's shares are trading above their 200-day moving average by 35.82%. Moreover, shares of Abeona Therapeutics, which focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, have an RSI of 48.09. Gain free access to the research report on ABEO at: www.wallstequities.com/registration/?symbol=ABEO
On Tuesday, Laval, Canada-based Acasti Pharma Inc.'s stock saw a rise of 11.50%, to close the day at $1.26. A total volume of 1.23 million shares was traded, which was higher than their three months average volume of 800.05 thousand shares. The Company's shares have advanced 6.78% in the last month. The stock is trading below its 50-day moving average by 5.65%. Additionally, shares of Acasti Pharma, which focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases, have an RSI of 55.24. Register for your free report coverage on ACST at: www.wallstequities.com/registration/?symbol=ACST
Shares in Summerville, South Carolina headquartered Aeterna Zentaris Inc. ended the day flat at $2.40. A total volume of 376,016 shares was traded. The stock has gained 19.40% in the last month and 18.23% in the previous three months. The Company's shares are trading above their 50-day and 200-day moving averages by 10.52% and 29.77%, respectively. Furthermore, shares of Aeterna Zentaris, which engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health, have an RSI of 56.53. Get the free research report on AEZS at: www.wallstequities.com/registration/?symbol=AEZS
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32- 044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/biotech-stocks-research-reports-released-on-22nd-century-abeona-therapeutics-acasti-pharma-and-aeterna-zentaris-300587371.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!